Quantitative Adenovirus Assay Better Informs Post-Transplant Care: Joseph Yao, M.D.

Answers from the Lab

Jun 17, 2025•12 min•Ep. 356

--:--

Listen in podcast apps:

Apple Podcasts

Spotify

Download

Listen to this episode in Metacast mobile app

Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

Joseph Yao, M.D., explains how Mayo Clinic Laboratories' new quantitative assay (Mayo ID: ADVQU) goes beyond qualitative testing to evaluate transplant patients for adenovirus infection. Adenovirus can cause life-threatening disease in immunocompromised transplant patients, especially children.

(01:14)
Could you give us a brief overview of this assay?

(02:06)
Can you explain the differences of the qualitative and quantitative methods and why we made the change to a quantitative adenovirus method?

(04:00)
When is this test typically ordered for transplant patients? Is it used throughout their treatment?

(06:56)

Could an immunocompromised person be unknowingly infected?

(07:31)

Is our quantitative method approved for pediatric patients?

(08:00)

How are the test results used to treat patients?

(10:36)

What other infections might providers consider alongside adeovirus?

For the best experience, listen in Metacast app for iOS or Android